UTSA to use the benefits of organosulfur in therapeutics

UTSA to use the benefits of organosulfur in therapeutics

Within our bodies and in the natural environment, organosulfur compounds are commonly available. Organosulfur has included onions, shallots, and even cauliflower. Medical research shows that they can guard against obesity, heart disease and even diabetes if they are ingested. There is also proof of the antiviral and antibacterial applications of these compounds. Approximately a quarter of all drugs are currently using OSCs.

The use of sulfur atoms in the manufacture of medicines, though, is a double-edged sword. The addition of sulfur into a molecule is difficult because presently available chemical instruments do not allow researchers to inject sulfur into high precision molecules. This shortcoming affects the ability of researchers to make chemicals that might one day become medications, as well as the potential efficacy of new drugs that rely on a particular structure of artificial sulfur molecules. UTSA also conducted work aimed at overcoming this roadblock to promote the development of new medicines.

“Our ultimate goal is to build a wide range of artificial sulfur-containing compounds that will become readily accessible for biological synthesis and drug development applications,” says Associate Professor Oleg Larionov, chief investigator at the UTSA Department of Chemistry for this project. We want to contribute to improving human health care through the more efficient synthesis of small molecule biological samples and curative agents. ”

Sulfur is the most common atom in small molecule pharmaceuticals after oxygen and nitrogen, and one-quarter of the small molecule drugs most prescribed are organosulfur compounds. More than 37% of all FDA-approved organosulfur drugs at the functional group level contain the sulfonyl group, stressing the importance of this particular group in drug design. The latest synthesis methods that are used to produce organosulfur compounds are complex, for example, chemists frequently fail to synthesize organosulfur substances with a specific structural geometry. Existing syntheses usually result in material mixtures of multiple isomers of chemo, regio, and stereo. Compounds with different structures of chemo-, regio-and stereo are made by the same atom types and numbers but assembled in different ways.

Professor Larionov intends to create methods to improve the result of the synthesis with particular chemo-, regio-and stereoselectivity of these sulfur-containing products.

The UTSA team will use more than $1 million in grants from the Government health Institutes to enhance these therapeutic agents ‘ production.

UTSA scientists plan to use intermediate oxidation states of organosulfur materials, in specific sulfinates, to resolve the industry’s limitations of existing methods, including the lack of efficient methods to synthesize sulfinates directly from plentiful catalysts.

“We want modern solutions simplified and long-standing medicinal chemistry problems solved,” says Larionov. “The basis for future medicinal chemistry research is our efforts and discoveries.”